CAMP4 Therapeutics misses 2025 EPS expectations

CAMP4 Therapeutics

05/03/2026 21:19

Overview

Biopharmaceutical firm's 2025 EPS missed analyst expectations, reporting a net loss of $80.4 mln

Company entered strategic collaboration with GSK, receiving $17.5 mln upfront

Company raised $80 mln through private placement and stock offering, extending cash runway into 2028

Outlook

CAMP4 expects Phase 1/2 trial for SYNGAP1 program in 2H 2026

Company collaborates with GSK for RNA-based therapeutics, eligible for milestone payments

CAMP4 extends cash runway into 2028 through recent funding activities

Result Drivers

NON-CASH LOSS - Co cited a $29.8 mln non-cash loss recognized due to a change in fair value of the derivative tranche liability related to its September private placement as key driver of net loss

GSK COLLABORATION - Co entered strategic collaboration with GSK for RNA-based therapeutics, receiving $17.5 mln upfront and potential milestone payments

Company press release: ID:nGNX4k8Q58

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
Miss
-$2.65
-$1.91 (4 Analysts)
FY Income From Operations
-$52.56 mln
FY Operating Expenses
$56.05 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for CAMP4 Therapeutics Corp is $8.00, about 96.1% above its March 4 closing price of $4.08

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)